About Egalet Corp
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: EGLT
- Previous Close: $4.93
- 50 Day Moving Average: $5.25
- 200 Day Moving Average: $6.92
- 52-Week Range: $24,614,000.00 - $4.34
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.64
- P/E Growth: 0.00
- Market Cap: $121.35M
- Outstanding Shares: 24,614,000
- Beta: 0.55
- Net Margins: -251.79%
- Return on Equity: -127.84%
- Return on Assets: -51.10%
Companies Related to Egalet Corp:
- Debt-to-Equity Ratio: 3.21%
- Current Ratio: 4.36%
- Quick Ratio: 4.30%
What is Egalet Corp's stock symbol?
Egalet Corp trades on the NASDAQ under the ticker symbol "EGLT."
Where is Egalet Corp's stock going? Where will Egalet Corp's stock price be in 2017?
4 brokers have issued 12-month price targets for Egalet Corp's stock. Their predictions range from $8.00 to $15.00. On average, they expect Egalet Corp's stock price to reach $11.88 in the next twelve months.
When will Egalet Corp announce their earnings?
Egalet Corp is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.
What are analysts saying about Egalet Corp stock?
Here are some recent quotes from research analysts about Egalet Corp stock:
Cantor Fitzgerald analysts commented, "Does the Label Differentiate? In the ADF morphine space there are already two approved products. ARYMO will launch with the label of IV abuse deterrence with the oral data. Though the IV label will be unique to ARYMO, we don’t believe that physicians or payors will be that explicit in differentiation. Embeda covers both oral and nasal with MorphaBond covering nasal only. Even with ARYMO expected to get nasal added to the label in 2018, no currently approved morphine ADF covers all routes. Our research, though limited due to few launches, seems to favor a comprehensive label in the conversion strategy. Tapering Launch Expectations: We are tapering our launch expectations around ARYMO as we see a more difficult commercial path given the ARYMO label. In a promotionally sensitive space like pain, a small sales force like EGLT’s may struggle for voice." (1/24/2017)
According to Zacks Investment Research, "Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom. " (1/13/2017)
Who owns Egalet Corp stock?
Egalet Corp's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.27%), Franklin Resources Inc. (11.10%), Federated Investors Inc. PA (9.67%), State Street Corp (1.30%), EcoR1 Capital LLC (0.90%) and Wall Street Associates (0.60%). Company insiders that own Egalet Corp stock include Deanne F Melloy, Jeffrey M Dayno, Mark Strobeck, Paul Varki, Robert S Radie and Stan Musial.
Who sold Egalet Corp stock? Who is selling Egalet Corp stock?
Egalet Corp's stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates. Company insiders that have sold Egalet Corp stock in the last year include Deanne F Melloy, Jeffrey M Dayno, Mark Strobeck, Paul Varki, Robert S Radie and Stan Musial.
Who bought Egalet Corp stock? Who is buying Egalet Corp stock?
Egalet Corp's stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Federated Investors Inc. PA, EcoR1 Capital LLC, State Street Corp, Flinton Capital Management LLC, Marshall Wace LLP, Tyers Asset Management LLC and Raymond James Financial Services Advisors Inc..
How do I buy Egalet Corp stock?
Shares of Egalet Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Egalet Corp stock cost?
One share of Egalet Corp stock can currently be purchased for approximately $4.93.